Cochlear Limited (ASX: COH) is the global leader in implantable hearing devices that transform the way people understand and treat hearing loss. It is worth noting that hearing loss is prevalent and under-treated, as highlighted in a recent study by WHO, which estimated that over 5 per cent of the world’s population has a disabling hearing loss and by 2050 it is expected that it will rise to one in every ten people.
With this in mind, the Group launched Nucleus Smart App for Android™ which will offer a significant connectivity for people who have a Nucleus® 7 Sound Processor. The biggest benefit of this is that user can now control their hearing with the Nucleus Smart App from a compatible Android device that will allow them to monitor and adjust their settings.
Cochlear has been working to deliver a world-class technology to Android smartphone users via the Nucleus Smart App. Moreover, the Group has added a new control feature called ForwardFocus to the Nucleus Smart App to nullify the noise from the background and users can have a better control on their listening environment. These new additions have got all kinds of regulatory approval in many markets including Australia, the US and Europe. Cochlear implants have been established as the standard of care for new born across many developed markets. The Group has been working towards its strategic priorities like towards its operational improvement and is making continuous improvement in R&D and is investing almost its 12 per cent of revenue in R&D.
The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkine.com.au and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). The information on this website has been prepared from a wide variety of sources, which Kalkine Pty Ltd, to the best of its knowledge and belief, considers accurate. You should make your own enquiries about any investments and we strongly suggest you seek advice before acting upon any recommendation. Kalkine Pty Ltd has made every effort to ensure the reliability of information contained in its newsletters and websites. All information represents our views at the date of publication and may change without notice. To the extent permitted by law, Kalkine Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services. There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. The link to our Terms & Conditions has been provided please go through them and also have a read of the Financial Services Guide. On the date of publishing this report (mentioned on the website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.